PRESSEMITTEILUNGEN

Paris (ots/PRNewswire) – Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The first pooled analysis using patient-level data from randomized clinical trials demonstrated that adding Lantus(R) (insulin glargine [rDNA] injection) to patients with type 2 diabetes, uncontrolled on oral antidiabetic drug therapy (OADs), was associated with a greater reduction in A1C levels and lower incidence of any hypoglycemia versus all comparators (OADs, NPH, lispro, premix).

In the second pooled analysis of clinical studies, “patients with type 2 diabetes, who used Lantus(R) as monotherapy or added it to one baseline oral antidiabetic agent, demonstrated a greater reduction in A1C with lower risk of hypoglycemia than those taking two OADs, with a most significant reduction when Lantus(R) was added to metformin alone versus other OADs [sulfonylurea alone or sulfonylurea plus metformin],” said Dr. Jack Leahy of the University of Vermont College of Medicine and principal investigator of one of the studies.

Better Efficacy and Goal Attainment Demonstrated with Insulin Glargine versus All Comparators[i]

“Efficacy and Goal Attainment with Insulin Glargine vs Comparators” [presentation number 976]: This pooled analysis looked at nine clinical studies where insulin-naive patients with type 2 diabetes uncontrolled on OADs were randomized to add Lantus(R) (n=1,462) or comparators (OADs, NPH, lispro or premix; n=1,476) to their treatment regimen. Results showed that initiating Lantus(R) in patients uncontrolled on OADs was associated with better efficacy and goal attainment overall versus all comparators across the A1C continuum and when compared to OADs when baseline A1C was greater than or equal to 8.0 percent.

Outcomes showed:

– A1C reductions at week 24 were greater with Lantus(R) versus
all comparators (p

Trackback URL

Antidiabetic Agent, European Association For The Study Of Diabetes, Goal Attainment, Insulin Glargine, Lantus Insulin, Naive Patients, Oads, Oral Antidiabetic Drug, Patient Level, Patients With Type, Presentation Number, Prnewswire, Randomized Clinical Trials, Sanofi Aventis, Stockholm Sweden, Treatment Regimen, Type 2 Diabetes, University Of Vermont, University Of Vermont College Of Medicine, Vermont College